FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

147 letters match. Newest first.

  1. Biopreventative Company LLC dba Biopreventative

    FDA told Biopreventative its website claim that compounded tadalafil is "commonly known as Cialis" misbrands the drug.

    Low
  2. Sprout Health Partners LLC dba Sprout Health

    FDA warned telehealth seller Sprout Health that its website's claim compounded semaglutide and tirzepatide are FDA-approved makes the drugs misbranded.

    Low
  3. Master Pharmaceuticals Group

    FDA warned Master Pharmaceuticals Group that its website sold compounded semaglutide and tirzepatide with false or misleading claims.

    High risk
  4. TRYM Health, Inc. dba TRYM Health

    FDA told telehealth seller TRYM Health its website claims for compounded semaglutide and tirzepatide are false and misleading, making the drugs misbranded.

    Medium
  5. HealBerry

    FDA warned HealBerry that claiming compounded semaglutide has the 'same active ingredient as Ozempic and Wegovy' misbrands its drugs.

    Medium
  6. Reset IV, LLC dba Reset IV

    FDA warned Reset IV that its website misbrands compounded semaglutide and tirzepatide by claiming they are the same as FDA-approved drugs.

    Medium
  7. inspire.clinic

    FDA warned telehealth site inspire.clinic that claims its compounded semaglutide and tirzepatide are similar to Ozempic or Mounjaro misbrand the drugs.

    Low
  8. Bioverse, Inc. dba Bioverse

    FDA warned Bioverse that its website made false or misleading claims for compounded semaglutide and tirzepatide drugs.

    Low
  9. SimpleRx

    FDA warned SimpleRx that its website falsely implied compounded semaglutide and tirzepatide were Ozempic or Zepbound.

    High risk
  10. Elevate Your Wellness LLC, dba Elevated

    FDA warned Elevated that its website offered compounded semaglutide and tirzepatide with misleading claims they match FDA-approved drugs.

    Low
  11. Cosmo Medical Spa dba Cosmo Med Spa

    FDA warned Cosmo Med Spa over its website selling compounded semaglutide with claims implying it is FDA-approved Ozempic.

    Medium
  12. EvoLife Wellness

    FDA warned EvoLife Wellness that its website wrongly calls compounded semaglutide and tirzepatide "FDA-Approved," making the drugs misbranded.

    Medium
  13. eDrugstore

    FDA warns eDrugstore over claims that compounded tirzepatide is FDA-approved, making drugs misbranded (falsely promoted).

    High risk
  14. Nuvo Life Health Inc. dba Nuvo Life Health

    FDA warned Nuvo Life Health that its website sold compounded semaglutide and tirzepatide with misleading claims comparing them to FDA-approved drugs.

    Medium
  15. SemaBio

    FDA warned SemaBio that its website sold compounded semaglutide and called it 'generic semaglutide,' a false or misleading claim.

    Low
  16. directmeds.com, Inc. dba DirectMeds

    FDA warned DirectMeds that its website sold compounded semaglutide and tirzepatide with false or misleading claims implying they match FDA-approved drugs.

    High risk
  17. Hims & Hers Health, Inc. dba Hims

    FDA warns Hims that compounded semaglutide website claims are false or misleading and misbrand the drugs.

    High risk
  18. MedClub by Dr. Jenn

    FDA warns MedClub by Dr. Jenn over unapproved compounded retatrutide and misleading semaglutide claims on its website.

    High risk
  19. Mane & Steel, LLC. dba Mane & Steel

    FDA warns Mane & Steel over false 'clinically proven' claims for compounded semaglutide.

    Low
  20. Lumimeds

    FDA warns Lumimeds over website claims implying its compounded semaglutide and tirzepatide are FDA-approved.

    High risk
  21. GLP-1 Solution

    GLP-1 Solution sells unapproved compounded retatrutide online and misleadingly compares semaglutide and tirzepatide to FDA-approved brand drugs.

    High risk
  22. ASN-LABS

    ASN-LABS marketed unapproved compounded retatrutide and misleading semaglutide claims online, FDA says.

    High risk
  23. Body Good Studio

    FDA warned Body Good Studio over its website selling compounded semaglutide with a false claim that it matches Ozempic and Wegovy.

    High risk
  24. Canada Med Stop

    Canada Med Stop marketed compounded semaglutide online as FDA-approved and generic, making the drugs misbranded.

    Medium
  25. All American Wellness

    FDA warned telehealth seller All American Wellness that its website wrongly compares compounded semaglutide and tirzepatide to Ozempic and Mounjaro.

    Low
  26. Healthy Male

    FDA warns Healthy Male that its website sells compounded tirzepatide with false or misleading 'clinically proven' weight-loss claims.

    Low
  27. Intimate Rose

    FDA warned Intimate Rose that its website sells compounded semaglutide and tirzepatide with misleading claims that they match approved drugs.

    High risk
  28. Invigorate Med Spa

    Invigorate Med Spa's website claimed compounded semaglutide and tirzepatide were Wegovy and Mounjaro, making them misbranded.

    Low
  29. Dr. Gater’s Weight Loss & Wellness

    Dr. Gater’s Weight Loss & Wellness marketed compounded semaglutide and tirzepatide with false or misleading FDA-approval and generic-Ozempic claims.

    Medium
  30. Remedy Meds

    FDA warns Remedy Meds that its telehealth site misleadingly labels pharmacy-made semaglutide and tirzepatide with approved-drug comparisons.

    Low
  31. EA WORKS Limited Liability Company dba Trust Labs

    FDA warned Trust Labs it sold unapproved compounded retatrutide and made false FDA-approval claims for semaglutide and tirzepatide online.

    High risk
  32. Fancy Meds, LLC dba Fancy Meds

    FDA warns Fancy Meds that its compounded semaglutide and tirzepatide website claims are false or misleading.

    Low
  33. Matthew Stern, CEO MyStart Health LLC.

    FDA warns MyStart Health over 'Generic Ozempic' claims for compounded semaglutide.

    Low
  34. Elite Health Center

    FDA warned Elite Health Center that its website falsely implied compounded semaglutide was FDA-approved, making the drugs misbranded.

    Low
  35. Curex

    FDA warned Curex that its website ads for compounded semaglutide and tirzepatide are false or misleading.

    High risk
  36. Healthon Inc. dba Healthon

    FDA warned Healthon over unapproved compounded semaglutide and tirzepatide sold online with false 'FDA-approved' and 'same as' claims.

    High risk
  37. Eli Lilly and Company

    FDA says Eli Lilly's sponsored Zepbound video omitted risk and use information, misbranding the drug.

    Low
  38. www.peacefulmeds.com

    FDA warned www.peacefulmeds.com for selling unapproved, misbranded opioids, benzodiazepines, and injectable semaglutide to U.S. consumers online.

    High risk
  39. Prime Vitality, Inc. dba Prime Peptides

    FDA warned Prime Peptides that its website sells Semaglutide and Retatrutide as unapproved new drugs for weight loss and diabetes.

    High risk
  40. Nomida.biz

    FDA warned Nomida.biz over its website selling unapproved and misbranded semaglutide and tirzepatide drugs to U.S. consumers.

    High risk
  41. www.semaspace.com

    FDA warned semaspace.com for selling unapproved, misbranded injectable semaglutide drugs online without prescriptions.

    High risk
  42. www.gorillahealing.com

    FDA warned gorillahealing.com for selling unapproved, misbranded semaglutide and tirzepatide drugs to U.S. consumers online.

    High risk
  43. citypharma.us

    FDA warned citypharma.us for selling unapproved, misbranded opioid, benzodiazepine, and stimulant drugs to U.S. consumers online.

    High risk
  44. yourtramadol.com

    FDA warned yourtramadol.com for selling unapproved and misbranded tramadol opioid products to U.S. consumers online.

    High risk
  45. kubapharm.com

    FDA and DEA warned kubapharm.com it unlawfully sells high-abuse-risk stimulants, including Adderall, online without required registrations or prescriptions.

    High risk
  46. premiumlightsupplier.com

    FDA and DEA warned premiumlightsupplier.com that it unlawfully sells Schedule II stimulants, including Adderall, online without prescriptions or DEA registration.

    High risk
  47. Extrapharmacy.ru

    FDA warned Extrapharmacy.ru for selling unapproved, mislabeled prescription drugs, including COVID-19 treatments, to U.S. consumers online.

    High risk